Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Boehringer Ingelheim Nintedanib gets USFDA Breakthrough Therapy Designation for chronic ILDs

      Boehringer Ingelheim Nintedanib gets USFDA Breakthrough Therapy Designation for chronic ILDs

      Medical Dialogues Bureau13 Oct 2019 9:22 AM IST
      New Delhi: Boehringer Ingelheim announced recently that the U.S. Food and Drug Administration (USFDA) granted Breakthrough Therapy Designation to...
      Pfizer, Akcea enter licensing agreement for investigational antisense therapy AKCEA-ANGPTL3-LRx

      Pfizer, Akcea enter licensing agreement for investigational antisense therapy AKCEA-ANGPTL3-LRx

      Medical Dialogues Bureau13 Oct 2019 9:15 AM IST
      New Delhi: Pfizer Inc. and Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc, recently announced that the companies...
      Cadila Healthcare largest API manufacturing site clears USFDA inspection

      Cadila Healthcare largest API manufacturing site clears USFDA inspection

      Medical Dialogues Bureau12 Oct 2019 11:41 AM IST
      The US Food and Drug Administration (USFDA) inspected the company's active pharmaceutical ingredients (API) manufacturing facility at Dabhasa from...
      Eli Lilly migraine drug Lasmiditan wins USFDA approval

      Eli Lilly migraine drug Lasmiditan wins USFDA approval

      Medical Dialogues Bureau12 Oct 2019 10:00 AM IST
      Eli Lilly acquired Reyvow, formerly called lasmiditan, in a deal here worth about $960 million when it bought CoLucid Pharmaceuticals Inc in early...
      GSK collaborates with Lyell Immunopharma on cancer cell therapies

      GSK collaborates with Lyell Immunopharma on cancer cell therapies

      Medical Dialogues Bureau12 Oct 2019 9:15 AM IST
      Combining GSK plc's strong cell and gene therapy programmes with Lyell's technologies may allow the joint research team to maximize the activity and...
      Aurobindo Pharma Unit-7 documents inaccurate, misleading: USFDA

      Aurobindo Pharma Unit-7 documents inaccurate, misleading: USFDA

      Medical Dialogues Bureau11 Oct 2019 10:00 AM IST
      "The responsibilities and procedures applicable to the quality control unit are not fully followed. Several lists of documents requested were either...
      Biocon arm signs licensing agreement with Evotec for biosimilar asset

      Biocon arm signs licensing agreement with Evotec for biosimilar asset

      Medical Dialogues Bureau11 Oct 2019 9:45 AM IST
      Through this in-licensing deal, Biocon Biologics has expanded its current therapeutic basket of biosimilars going beyond diabetes, oncology and...
      Torrent Pharma shares slump 3pc on USFDA warning letter for Gujarat facility

      Torrent Pharma shares slump 3pc on USFDA warning letter for Gujarat facility

      Medical Dialogues Bureau11 Oct 2019 9:15 AM IST
      Torrent Pharma does not believe that the warning letter will have an impact on the disruption of supplies or the existing revenues from operations of...
      Aurobindo Pharma rises 5 pc post clarification on USFDA observations for Unit-7

      Aurobindo Pharma rises 5 pc post clarification on USFDA observations for Unit-7

      Medical Dialogues Bureau10 Oct 2019 11:56 AM IST
      A clarification was sought from Aurobindo Pharma regarding declining share prices on the back of USFDA observations.New Delhi: Shares of Aurobindo...
      Torrent Pharma Indrad facility gets USFDA warning letter

      Torrent Pharma Indrad facility gets USFDA warning letter

      Medical Dialogues Bureau10 Oct 2019 11:44 AM IST
      This action by the United States Food and Drug Administration (USFDA) follows earlier intimation received from the regulator in August 2019, wherein...
      Zydus Cadila gets USFDA nod for Colesevelam Hydrochloride tablets for lowering cholesterol

      Zydus Cadila gets USFDA nod for Colesevelam Hydrochloride tablets for lowering cholesterol

      Medical Dialogues Bureau10 Oct 2019 11:34 AM IST
      Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Colesevelam Hydrochloride tablets,...
      Galderma wins USFDA nod for AKLIEF Cream to treat acne

      Galderma wins USFDA nod for AKLIEF Cream to treat acne

      Medical Dialogues Bureau10 Oct 2019 9:30 AM IST
      New Delhi: Galderma, announced recently that the U.S. Food and Drug Administration (USFDA) has approved AKLIEF (trifarotene) Cream, 0.005% for the...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok